The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 53.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.66%)
Open: 54.50
High: 54.50
Low: 54.50
Prev. Close: 54.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Dealings by Directors

11 Mar 2022 13:10

RNS Number : 5388E
MyCelx Technologies Corporation
11 March 2022
 

11 March 2022

 

MYCELX Technologies Corporation

 

Dealings by Directors

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company, announces, further to the Placing and Subscription this morning, the following participation by Directors of the Company.

 

Director

Shares held prior to Admission

New Shares Purchased

Shares held post Admission

Percentage of Enlarged Issued Share Capital

Thomas Lamb

25,000

267,175

292,175

1.28%

Connie Mixon

2,514,469

38,167

2,552,636

11.18%

Andre Schnabl

8,246

38,167

46,413

0.20%

 

 

Total Voting Rights

In conformity with the FCA's Disclosure Guidance and Transparency Rules (the "Rules") provision 5.6.1, the Company would like to notify the market that following Admission on 21 March 2022 its issued share capital will consist of 22,828,023 Common Shares of US$0.025 each.

Shareholders should use 22,828,023 as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Rules.

Terms and definitions used in this announcement shall have the same meaning as ascribed to them in the Placing and Subscription Announcement released at 7:00 a.m. on 11 March 2022, unless the context requires otherwise.

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity, Nominated Adviser

Henry Fitzgerald-O'Connor

Gordon Hamilton

 

 

Tel: + 44 20 7523 8000

 

Notifications of transactions of persons discharging managerial responsibility or connected persons

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Thomas Lamb

2

 

Reason for the notification

a)

 

Position/status

 

Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Mycelx Technologies Corporation

b)

 

LEI

 

213800UJZINIK2VD1G48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Identification code

 

Common shares of US$0.025

USU624551235

b)

 

Nature of the transaction

Purchase of Common Shares

c)

 

Price(s) and volume(s)

Price(s)

 

Volume(s)

£0.50

267,175

d)

 

Aggregated information

- Aggregated volume

- Price

 

n/a

n/a

 

e)

 

Date of the transaction

 

11 March 2022

f)

 

Place of the transaction

London Stock Exchange

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Connie Mixon

2

 

Reason for the notification

a)

 

Position/status

 

Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Mycelx Technologies Corporation

b)

 

LEI

 

213800UJZINIK2VD1G48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Identification code

 

Common shares of US$0.025

USU624551235

b)

 

Nature of the transaction

Purchase of Common Shares

c)

 

Price(s) and volume(s)

Price(s)

 

Volume(s)

£0.50

38,167

d)

 

Aggregated information

- Aggregated volume

- Price

 

n/a

n/a

 

e)

 

Date of the transaction

 

11 March 2022

f)

 

Place of the transaction

 

London Stock Exchange

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Andre Schnabl

2

 

Reason for the notification

a)

 

Position/status

 

Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Mycelx Technologies Corporation

b)

 

LEI

 

213800UJZINIK2VD1G48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Identification code

 

Common shares of US$0.025

USU624551235

b)

 

Nature of the transaction

Purchase of Common Shares

c)

 

Price(s) and volume(s)

Price(s)

 

Volume(s)

£0.50

38,167

d)

 

Aggregated information

- Aggregated volume

- Price

 

n/a

n/a

 

e)

 

Date of the transaction

 

11 March 2022

f)

 

Place of the transaction

 

London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHJBMJTMTMBBIT
Date   Source Headline
4th Mar 20167:00 amRNSTrading Update
11th Jan 20165:30 pmRNSHolding(s) in Company
29th Dec 20152:23 pmRNSHolding(s) in Company
18th Dec 201510:13 amRNSHolding(s) in Company
15th Dec 20155:25 pmRNSHolding(s) in Company
15th Dec 20155:24 pmRNSHolding(s) in Company
11th Dec 20157:00 amRNSTrading Update
3rd Dec 201511:33 amRNSBlocklisting Interim Review
1st Oct 20157:00 amRNSProgress Update on Trials
10th Sep 20157:00 amRNSHalf Yearly Report
28th Aug 20157:00 amRNSRestricted Common Shares to be Traded in CREST
20th Aug 20157:00 amRNSDirector Resignation
17th Aug 20157:00 amRNSProgress Report on Trials and Cost Reduction
29th Jul 20152:01 pmRNSHolding(s) in Company
22nd Jul 20157:00 amRNSTrading Statement
1st Jul 20157:00 amRNSChange of Adviser
5th Jun 20157:00 amRNSDirector/PDMR Shareholding
28th May 20159:48 amRNSBlocklisting Interim Review
21st May 20153:01 pmRNSDirector/PDMR Shareholding
19th May 20154:01 pmRNSResult of Annual Meeting
19th May 20157:00 amRNSAnnual Meeting Statement
17th Apr 20157:00 amRNSMailing of 2014 Annual Report & Notice of AGM
20th Mar 20157:00 amRNS2014 Preliminary Results
15th Jan 20155:39 pmRNSTrading Update
5th Jan 20157:00 amRNSClose of US Placing
2nd Jan 201512:00 pmRNSHolding(s) in Company
22nd Dec 201412:54 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSEquity Placing
2nd Dec 20147:00 amRNSEquity Placing
27th Nov 20143:58 pmRNSBlocklisting Interim Review
19th Nov 20147:00 amRNSTrading Statement
12th Sep 20147:00 amRNSHalf Year Results Statement
26th Aug 20147:00 amRNSMiddle East Contract Win
7th Jul 20147:00 amRNSHalf Year Trading Update & Contract Wins
13th May 20143:31 pmRNSResult of Annual Meeting
29th Apr 20144:44 pmRNSBlocklisting Interim Review
22nd Apr 201410:02 amRNSAnnual Report & Accounts Posted
20th Mar 20147:00 amRNS2013 Preliminary Results
30th Jan 20147:00 amRNSYear End Trading Update & Contract Wins
10th Dec 20133:29 pmRNSTotal Voting Rights
4th Dec 20133:24 pmRNSHolding(s) in Company
26th Nov 20137:00 amRNSFast-to-market lease programme yields new leasings
30th Oct 20133:21 pmRNSDirector/PDMR Shareholding
29th Oct 20131:56 pmRNSBlocklisting Interim Review
16th Oct 20133:12 pmRNSDirector Shareholding / Warrant Exercise
3rd Oct 20137:00 amRNSInvestor Presentation
12th Sep 20137:00 amRNSHalf Year Results Statement
19th Aug 20139:06 amRNSNotice of Results
7th Aug 20139:29 amRNSBalance of respective lines of stock
10th Jun 20135:16 pmRNSChange of Main Office Address

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.